[ad_1]
U.S. Medicare administrative contractor Novitas has delayed a final decision on whether to remove Cxbladder from its list of approved tests.
Pacific Edge’s CXbladder test.
New Zealand Stock Exchange-listed cancer diagnostics company Pacific Edge said it had been told it would have to wait a while before deciding whether to continue working with the US health insurance system, a vital customer.
Novitas is the Medicare Administrative Contractor for the Pacific
Want to read more? It’s easy.
Choose the best value subscription option
personal
Group Members
NBR Market
Annual Premium Online Subscription
NZD 499.00 / Per year
NZD 399.00/year
Offer ends on July 31English Stone
Monthly Premium Online Subscription
NZD 44.95 per month
Smartphone subscription only
NZD 24.95/month
Premium Group Membership 10 users
NZD 350+ Goods and Services Tax / Monthly
$35 per user – payable monthly by credit or debit card
Premium Group Membership 20 users
NZD 600+ Goods and Services Tax / Monthly
$30 per user – payable monthly by credit or debit card
Premium Group Membership 50 users
NZD 1250+ Goods and Services Tax / Monthly
$25 per user – payable monthly by credit or debit card
Premium Group Membership 100 users
NZD 1875+ Goods and Services Tax / Monthly
$18.75 per user – payable monthly via credit or debit card
Annual Premium Online Subscription + NBR Marketplace
NZ$499.00 / year
Already have an account? Log in
© All content is copyrighted by NBR. No reproduction in any form is permitted without permission, even if you have a paid subscription.
[ad_2]
Source link
